Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -7.89% | 30.92% | 141.79% | 345.90% | 1,466.56% |
| Total Other Revenue | 21,267.57% | 316.95% | -98.08% | -98.08% | -98.08% |
| Total Revenue | -6.35% | 31.72% | 139.16% | 337.82% | 1,378.86% |
| Cost of Revenue | 22.57% | 40.03% | 61.47% | 76.77% | 102.70% |
| Gross Profit | -10.14% | 30.25% | 165.45% | 477.38% | 8,405.47% |
| SG&A Expenses | -21.56% | 1.46% | 36.52% | 48.25% | 62.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.53% | 33.36% | 57.49% | 71.54% | 93.85% |
| Operating Income | -9.80% | 31.36% | 174.29% | 535.91% | 15,563.86% |
| Income Before Tax | -10.55% | 33.36% | 184.97% | 532.69% | 61,353.81% |
| Income Tax Expenses | -14.06% | 83.33% | 2,565.33% | 5,064.81% | -- |
| Earnings from Continuing Operations | -9.49% | 21.75% | 106.31% | 381.96% | 47,103.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.49% | 21.75% | 106.31% | 381.96% | 47,103.63% |
| EBIT | -9.80% | 31.36% | 174.29% | 535.91% | 15,563.86% |
| EBITDA | -9.79% | 31.36% | 174.27% | 535.72% | 15,688.25% |
| EPS Basic | -9.85% | 21.03% | 103.87% | 377.33% | 45,333.33% |
| Normalized Basic EPS | -10.83% | 32.69% | 181.58% | 526.07% | 60,345.45% |
| EPS Diluted | -9.29% | 21.58% | 104.74% | 382.69% | 20,923.68% |
| Normalized Diluted EPS | -10.31% | 33.20% | 182.36% | 531.74% | 29,377.27% |
| Average Basic Shares Outstanding | 0.55% | 0.90% | 1.26% | 1.07% | 0.88% |
| Average Diluted Shares Outstanding | 0.01% | 0.08% | 0.15% | 0.79% | 1.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |